secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2024-12-17T23:59:59+00:00
Accession:  0001437749-24-037688
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia commercially launches Morph DNA steerable introducer product family
-----------------------------------------------------------------------------

- Morph DNA steerable introducer family now commercially available; currently used in ongoing cell-therapy clinical trials.
- CEO Peter Altman says sales pipeline explored organically without a direct sales force or third-party partners.
- Anticipates final results of CardiAMP Heart Failure I trial and active enrollment in CardiAMP Heart Failure II by Q1 2025.
- Company remains focused on its FDA breakthrough-designated cell therapy for ischemic heart failure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774924037688/0001437749-24-037688-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774924037688/bcda20241217_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-037688

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer